Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06943755 · ClinicalTrials.gov registry record · Phase 2
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
A Phase 2 study of Pancreatic Neuroendocrine Tumor (pNET) and Extra-Pancreatic Neuroendocrine Tumor (epNET), sponsored by Exelixis.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 440
- Enrollment target
- 20
- Study locations
NCT06943755 is a Phase 2 study of Pancreatic Neuroendocrine Tumor (pNET) and Extra-Pancreatic Neuroendocrine Tumor (epNET) that is actively recruiting participants, run by Exelixis. The registered enrollment target is 440 participants. The trial reports 20 study locations across 14 states.
The verdict
NCT06943755, a Phase 2 study of Pancreatic Neuroendocrine Tumor (pNET) and Extra-Pancreatic Neuroendocrine Tumor (epNET), is actively recruiting participants, sponsored by Exelixis.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 440 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors.
Conditions Studied
Interventions
- DRUG Everolimus
- DRUG Zanzalintinib
Study Locations (20)
California
- Exelixis Clinical Site #18 - Beverly Hills
- Exelixis Clinical Site #16 - Los Angeles
- Exelixis Clinical Site #12 - Santa Monica
- Exelixis Clinical Site #29 - Vallejo
Arizona
- Exelixis Clinical Site #36 - Phoenix
- Exelixis Clinical Site #42 - Tucson
Florida
- Exelixis Clinical Site #35 - Jacksonville
- Exelixis Clinical Site #11 - Tampa
Michigan
- Exelixis Clinical Site #47 - Detroit
- Exelixis Clinical Site #1 - Grand Rapids
Alabama
- Exelixis Clinical Site #43 - Birmingham
District of Columbia
- Exelixis Clinical Site #19 - Washington D.C.
Kentucky
- Exelixis Clinical Site #9 - Lexington
Louisiana
- Exelixis Clinical Site #23 - Metairie
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 440 participants |
| Start Date | 2025-07-21 |
| Est. Completion | 2029-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06943755
The ClinicalTrials.gov registry entry for NCT06943755 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 440 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Exelixis, which has 48 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Pancreatic Neuroendocrine Tumor (pNET) appearing as the primary indexed condition, and to 2 interventions - of which Everolimus is the first listed.
NCT06943755 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT06943755 about?
NCT06943755 is a clinical study titled "Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors". The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors.
What is the current status of trial NCT06943755?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 440 participants. The study started on 2025-07-21. Estimated completion is 2029-06.
What conditions does trial NCT06943755 study?
This clinical trial studies the following conditions: Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET).
What interventions are being tested in trial NCT06943755?
The interventions under investigation include: Everolimus (DRUG), Zanzalintinib (DRUG).
Who is sponsoring clinical trial NCT06943755?
This trial is sponsored by Exelixis, which has 48 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06943755 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Pancreatic Neuroendocrine Tumor (pNET)
All registered trials for this condition
Extra-Pancreatic Neuroendocrine Tumor (epNET)
All registered trials for this condition
Alabama
All trials with a study site in Alabama
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.